Basal Cell Carcinoma of the Skin – Biological Behaviour of the Tumor and a Review of the Most Important Molecular Predictors of Disease Progression in Pathological Practice

Authors: V. Bartoš 1;  K. Adamicová 2;  M. Kullová 3;  M. Péč 4
Authors‘ workplace: Oddelenie patologickej anatómie FNsP v Žiline, Slovenská republika 1;  Ústav patologickej anatómie JLF UK a MFN v Martine, Slovenská republika 2;  Oddelenie dermatovenerológie FNsP v Žiline, Slovenská republika 3;  Ústav lekárskej biológie Jesseniovej lekárskej fakulty UK v Martine, Slovenská republika 4
Published in: Klin Onkol 2011; 24(1): 8-17
Category: Reviews


Basal cell carcinoma of the skin is currently the most frequent malignancy in human population. Basal cell carcinoma represents a heterogeneous group of tumors with a variable clinical and morphological picture. Based on its biological behaviour, we generally differentiate between indolent (superficial and nodular) and aggressive type (infiltrative, micronodular, and metatypical) of basal cell carcinoma. Because of the different biological characteristics of these tumors, it is questionable whether they are a part of a continuous spectrum of carcinogenesis, starting with indolent and ending with aggressive forms, or they represent separate developmental lines. In the current clinical practice, there is an increasing demand for identification of tumors that are prognostically more adverse and their impact on the overall health status of patients is more serious. Recent advances in pathology and molecular medicine allow identification of various biomarkers from tumor tissue that are significantly involved in the mechanisms of malignant cell transformation. Detection of these biomarkers is of great importance in predicting further clinical behaviour of the cancer. The authors of the paper present basic information about biological behaviour of cutaneous basal cell carcinoma and provide an overview of the most important biomarkers that influence the clinical outcome and disease progression and are detectable through a routine biopsy tissue examination. It is now necessary to search for novel histological and molecular parameters that, in the future, could have a prognostic value in diagnostic and therapeutic process of this disorder.

Key words:
basal cell carcinoma – biological behaviour – prognosis – disease progression


1. Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol 2006; 19 (Suppl 2): S127–S147.

2. Tilli CM, Van Steensen MA, Krkels GA et al. Molecular aetiology and pathogenesis of basal cell carcinoma. Br J Dermatol 2005; 152(6): 1108–1124.

3. Vantuchová Y, Čuřík R. Histological types of basal cell carcinoma. Scripta Medica (Brno) 2006; 79(5–6): 261–270.

4. Bozdogan O, Erkek E, Atasoy P et al. Bcl-2-related proteins, alpha-smooth muscle actin and amyloid deposits in aggressive and non-aggressive basal cell carcinoma. Acta Derm Venereol 2002; 82(6): 423–427.

5. Saldanha G, Fletcher A, Slater DN. Basal cell carcinoma: a dermatopathological and molecular biological update. Br J Dermatol 2003; 148(2): 195–202.

6. Bartoš V, Adamicová K, Kullová M et al. Bazocelulárny karcinóm kože – najvýznamnejšie rizikové a prognostické parametre ochorenia v klinickej praxi. Prakt Lék 2010; 90(3): 160–166.

7. Bolskahov S, Walker CM, Strom SS et al. p53 muta­tions in human aggressive and nonaggressive basal and squamous cell carcinomas. Clin Cancer Res 2003; 9(1): 228–234.

8. Kim MY, Park HJ, Baek SC et al. Mutations of the p53 and PTCH gene in basal cell carcinomas: UV mutation signature and strand bias. J Dermatol Sci 2002; 29(1): 1–9.

9. Watson A, Kent P, Alam M et al. GLI1 genotypes do not predict basal cell carcinoma risk: a case control study. Mol Cancer 2009; 8: 113.

10. Plevová P, Krutílková V, Puchmajerová A et al. Gorlinův syndrom. Klin Onkol 2009; 22 (Suppl): S34–S35.

11. Plevová P, Šilhánová E, Foretová L. Vzácné hereditární syndromy s vyšším rizikem vzniku nádorů. Klin Onkol 2006; 19 (Suppl): S68–S75.

12. Valdivielso M, Longo I, Sauárez R et al. Acrokeratosis paraneoplastica: Bazex syndrome. J Eur Acad Dermatol Venereol 2005; 19(3): 340–344.

13. Walling HW, Fosko SW, Geraminejad PA. Aggressive basal cell carcinoma: Presentation, pathogenesis, and management. Cancer Metastasis Rev 2004; 23(3–4): 389–402.

14. Marasa L, Marasa S, Sciancalepore G. Collagen IV, laminin, fibronectin, vitronectin. Comparative study in basal cell carcinoma. Correlation between basement membrane molecules expression and invasive potential. G Ital Dermatol Venereol 2008; 143(3): 169–173.

15. Hayakawa TJ, Pilavdzic D, Magro CM et al. The ultrastructure of aggressive – versus indolent – growth basal cell carcinoma: a comparative study (abstract). Lab Invest 1998; 78: 50A.

16. Adamicová K, Fetisovová Ž, Mellová Y et al. Invazívny typ bazocelulárneho karcinómu. Lekárske Listy 2004; 17: 4–5.

17. Adamicová K, Fetisovová Ž, Mellová Y a kol. Hodnotenie bazálnej membrány u morfeaformného (invazívneho) bazaliómu. Čes-slov Derm 2005; 80(2): 76–81.

18. Mostafa WZ, Mahfouz SM, Bosseila M et al. An immunohistochemical study of laminin in basal cell carcinoma. J Cutan Pathol 2010; 37(1): 68–74.

19. Kerkelä E, Saarialho-Kere U. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol 2003; 12(2): 109–125.

20. Majmudar G, Nelson BR, Jensen TC et al. Increased expression of stromelysin-3 in basal cell carcinomas. Mol Carcinog 1994; 9(1): 17–23.

21. Wagner SN, Ruhri C, Kunth K et al. Expression of stromelysin 3 in the stromal elements of human basal cell carcinoma. Diag Mol Pathol 1992; 1(3): 200–205.

22. Bayer-Garner IB, Dilday B, Sanderson RD et al. Syndecan-1 expression is decreased with increasing aggressivennes of basal cell carcinoma. Am J Dermatopathol 2000; 22(2): 119–122.

23. Bertheim U, Hofer PA, Engstrom-Laurent A et al. The stromal reaction in basal cell carcinomas. A prerequisite for tumour progression and treatment strategy. Br J Plast Surg 2004; 57(5): 429–439.

24. Boyd S, Tolvanen K, Virolainen S et al. Differential expression of stromal MMP-1, MMP-9 and TIMP-1 in basal cell carcinomas of immunosuppressed patients and controls. Virchows Arch 2008; 452(1): 83–90.

25. Pizzaro A, Benito N, Navarro P et al. E-cadherin expression in basal cell carcinoma. Br J Cancer 1994; 69(1): 157–162.

26. Pentel M, Helm KF, Maloney MM. Cell surface molecules in basal cell carcinomas. Dermatol Surg 1995; 21(10): 858–861.

27. Saldanha G, Ghura V, Potter L et al. Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation. Br J Dermatol 2004; 151(1): 157–164.

28. Law AM, Oliveri CV, Pacheco-Quinto X et al. Actin expression in purely nodular versus nodular-infiltrative basal cell carcinoma. J Cutan Pathol 2003; 30(4): 232–236.

29. Christian MM, Moy RL, Wagner RF et al. A correlation of alpha-smooth muscle actin and invasion in micronodular basal cell carcinoma. Dermatol Surg 2001; 27(5): 441–445.

30. Uzquiano MC, Prieto VG, Nash JW et al. Metastatic basal cell carcinoma exhibits reduced actin expression. Mod Pathol 2008; 21(5): 540–543.

31. Lee MW, Ahn SJ, Choi JH et al. Actin and calponin expression in basal cell carcinoma. Br J Dermatol 2004; 151(4): 934–936.

32. Abdelsayed RA, Guijarro-Rojas M, Ibrahim NA et al. Immunohistochemical evaluation of basal cell carcinoma and trichepithelioma using Bcl-2, Ki67, PCNA and p53. J Cutan Pathol 2000; 27(4): 169–175.

33. Baum HP, Meurer I, Unteregger G. Ki-67 antigen expression and growth pattern of basal cell carcinomas. Arch Dermatol Res 1993; 285(5): 291–295.

34. Horlock NM, Wilson GD, Daley F et al. Cellular proliferation characteristics of basal cell carcinoma: relationship to clinical subtype and histopathology. Eur J Surg Oncol 1997; 23(3): 247–252.

35. Naeyaert JM, Pauwels C, Geerts ML et al. CD-34 and Ki-67 staining patterns of basaloid follicular hamartoma are different from those in fibroepithelioma of Pinkus and other variants of basal cell carcinoma. J Cutan Pathol 2001; 28(10): 538–541.

36. Toth DP, Guenther LC, Shum DT. Proliferating cell nuclear antigen (PCNA); prognostic value in the clinical recurrence of primary basal cell carcinoma. J Dermatol Sci 1996; 11(1): 36–40.

37. Kazantseva IA, Khlebnikova AN, Babaev VR. Immunohistochemical study of primary and recurrent basal cell and metatypical carcinomas of the skin. Am J Dermatopathol 1996; 18(1): 35–42.

38. Cabral A, Van Haaften C, Boon ME. Proliferation patterns reflect architectural dedifferentiation: A study of nodular basal cell carcinoma. J Dermatol 2004; 31(4): 305–313.

39. Horlock N, Wilson GD, Daley FM et al. Cellular proliferation characteristics do not account for the behaviour of horrifying basal cell carcinoma. A comparison of the growth fraction of horrifying and non horrifying tumours. Br J Plast Surg 1998; 51(1): 59–66.

40. Lo Muzio L, Pannone G, Staibano S et al. WNT-1 expression in basal cell carcinoma of head and neck. An immunohistochemical and confocal study with regard to the intracellular distribution of beta-catenin. Anticancer Res 2002; 22(2A): 565–576.

41. Staibano S, Lo Muzio L, Pannone G et al. DNA ploidy and cyclin D1 expression in basal cell carcinoma of the haed and neck. Am J Clin Pathol 2001; 115(6): 805–813.

42. Cerroni L, Keri H. Aberrant bcl-2 protein expression provides a possible mechanism of neoplastic cell growth in cutaneous basal cell carcinoma. J Cutan Pathol 1994; 21(5): 398–403.

43. Staibano S, Lo Muzio L, Pannone G et al. Interaction between bcl-2 and P53 in neoplastic progression of basal cell carcinoma of the head and neck. Anticancer Res 2001; 21(6A): 3757–3764.

44. Kerr JF, Searle J. A suggested explanation for the paradoxically slow growth rate of basal-cell carcinomas that contain numerous mitotic figures. J Pathol 1972; 107(1): 41–44.

45. Mooney EE, Peris Ruis JM, O‘Neill A et al. Apoptotic and mitotic indices in malignant melanoma and basal cell carcinoma. J Clin Pathol 1995; 48(3): 242–244.

46. Staibano S, Lo Muzio L, Mezza E et al. Prognostic value of apoptotic index in cutaneous basal cell carcinomas of head and neck. Oral Oncol 1999; 35(6): 541–547.

47. Barrett TL, Smith KJ, Hodge JJ et al. Immunohistochemical nuclear staining for p53, PCNA, and Ki-67 in different histologic variants of basal cell carcinoma. J Am Acad Dermatol 1997; 37 (3 Pt 1): 430–437.

48. Shea CR, McNutt NS, Volkenandt M et al. Overexpression of p53 protein in basal cell carcinomas of human skin. Am J Pathol 1992; 141(1): 25–29.

49. Crowson AN, Magro CM, Pilavdzic D et al. Differential stromal p53 expression in human basal cell carcinoma (abstract). Lab Invest 1997; 76: 43A.

50. Crowson AN, Magro CM, Kadin M et al. Differential expression of bcl-2 oncogene in human basal cell carcinoma. Hum Pathol 1996; 27(4): 355–359.

51. Zagrodnik B, Kempf W, Seifert B et al. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and bcl-2. Cancer 2003; 98(12): 2708–2714.

52. Kaur P, Mulvaney M, Carlson JA. Basal cell carcinoma progression correlates with host immune response and stromal alterations: a histological analysis. Am J Dermatopathol 2006; 28(4): 293–307.

53. Hendrix JD Jr, Parlette HL. Micronodular basal cell carcinoma: a deceptive histologic subtype with frequent clinically undetected tumor extension. Arch Dermatol 1996; 132(3): 295–298.

54. Widgerow AD, Christofides T. Morpheic basal cell carcinoma: transformation or original pathology? Int Journal Plastic Surg 2006; 2(2): electronic letter.

55. Malone JP, Fedok FG, Belchis DA et al. Basal cell carcinoma metastatic to the parotid: report of a new case and review of the literature. Ear Nose Throat 2000; 79(7): 511–515, 518–519.

56. Bozikov K, Taggart I. Metastatic basal cell carcinoma: is infiltrative/morpheaform subtype a risk factor? Eur J Dermatol 2006; 16(6): 691–692.

57. Ting PT, Kasper R, Arlette JP. Metastatic basal cell carcinoma: report of two cases and literature review. J Cutan Med Surg 2005; 9(1): 10–15.

58. Lo JS, Snow SN, Reizner GT et al. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol 1991; 24 (5 Pt 1): 715–719.

59. Snow SN, Sahl W, Lo JS et al. Metastatic basal cell carcinoma. Report of five cases. Cancer 1994; 73(2): 328–335.

60. Bowman PH, Ratz JL, Knoepp TG et al. Basosquamous carcinoma. Dermatol Surg 2003; 29(8): 830–832.

61. Baum HP, Schmid T, Reichrath J. Integrin molecules: A clue to the non-metastasizing behaviour of basal cell carcinomas? Acta Derm Venereol 1996; 76(1): 24–27.

62. Giri DD, Gupta PK, Hoda RS. Cytologic diagnosis of metastatic basal cell carcinoma: Report of a case with immu­nocytochemical and molecular pathologic considera­tions. Acta Cytol 2000; 44(2): 232–236.

63. Sarma DP. Metastatic basal cell carcinoma: electron microscopic study of the primary and the metastatic lesion. South Med J 1980; 73(6): 799–801.

64. Yu M, Zloty D, Shapiro J et al. Superficial, nodular, and morpheiform basal-cell carcinomas exhibit distinct gene expression profiles. J Invest Dermatol 2008; 128(7): 1797–1805.

65. Kanitakis J, Euvrard S, Bourchany D et al. Expression of the nm23 metastasis-suppressor gene product in skin tumors. J Cutan Pathol 1997; 24(3): 151–156.

66. Baum HP, Schmid T, Schock G et al. Expression of CD44 isoforms in basal cell carcinomas. Br J Dermatol 1996; 134(3): 465–468.

Paediatric clinical oncology Surgery Clinical oncology
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account